Clinical trialNCT04626583CompletedPhase 1Interventional

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells

SponsorUniversity of Illinois at ChicagoEnrollment8CorneaCorneal DefectMesenchymal Stromal CellsSafety

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use digital conjunctival and corneal photography and corneal Scheimpflug Imaging, densitometry, and pachymetry for assessment of safety and corneal wound healing.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ali R Djalilian, MD
University of Illinois at Chicago
Principal Investigator
clinicaltrials.gov ↗
Charlotte E Joslin, OD, PhD
University of Illinois at Chicago
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Illinois, Department of Ophthalmology and Visual Sciences
Chicago, Illinois, United States
University of Maryland
Baltimore, Maryland, United States
Mass Eye and Ear Institute
Boston, Massachusetts, United States
University of Pennsylvania Scheie Eye Institute
Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Allogeneic MSC

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Mar 2021
Primary completion: 21 Apr 2023
Completion: 21 Apr 2023
Last update posted: 16 Dec 2024
Registered enrollment: 8
Registry id: NCT04626583

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.